The DOI matches its Crossref record.
Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections
Open accessAbstract
OBJECTIVE—Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. Thus, a comparison of efficacy between CSII and MDII should be undertaken only in studies that used rapid-acting analogs for both intensive regimens. RESEARCH DESIGN AND METHODS—We performed a pooled analysis of the randomized controlled trials that compared CSII and optimized MDII therapy using rapid-acting analogs in adults with type 1 diabetes. RESULTS—The three studies that met inclusion criteria provided data on 139 patients, representing 596 patient-months for CSII and 529 patient-months for MDII. Mean age was 38.5 years, with duration of diabetes of 18.0 years. The studies differed significantly in mean baseline A1c (7.95, 8.20, and 9.27%). The pooled estimate of treatment effect comparing the percentage reduction in A1c by CSII with that by MDII (CSII − MDII) was 0.35% (95% CI −0.10 to 0.80, P = 0.08) using a random effect to account for heterogeneity between studies. Importantly, the interaction between baseline A1c and treatment modality emerged as an independent predictor of treatment effect (CSII − MDII) (P = 0.002). The relative benefit of CSII over MDII was found to increase with higher baseline A1c. A model derived from these data predicts that in a patient with a baseline A1c of 10%, CSII would reduce the A1c by an additional 0.65% compared with MDII. Conversely, there would be no A1c benefit of CSII compared with MDII if baseline A1c were 6.5%. There was no significant difference between CSII and MDII in the rate of hypoglycemic events. CONCLUSIONS—When using rapid-acting insulin analogs in CSII and MDII regimens in adult patients with type 1 diabetes, insulin pump therapy is associated with better glycemic control, particularly in those individuals with higher baseline A1c. Thus, CSII emerges as an important modality for implementing intensive therapy and may be uniquely advantageous in patients with poor glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kramer, C. K., Zinman, B., & Retnakaran, R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-11-201312030-00008 · Cited by 961
Self-citationJeitler, K., Horvath, K., Berghold, A., Gratzer, T. W., Neeser, K., Pieber, T. R., & Siebenhofer, A. (2008) · Diabetologia · doi:10.1007/s00125-008-0974-3 · Cited by 375
Insulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Herman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey
Pickup, J. C., Yemane, N., Brackenridge, A., & Pender, S. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0192 · Cited by 123
Metadata
- Authors
- Retnakaran, R., Hochman, J., DeVries, J. H., Hanaire-Broutin, H., Heine, R. J., Melki, V., & Zinman, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 2590-2596
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2107926840
- Cited by
- 215
- References
- 0
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections. https://app.cochat.ai/papers/10.2337/diacare.27.11.2590
- The paper
- Retnakaran, R., Hochman, J., DeVries, J. H., Hanaire-Broutin, H., Heine, R. J., Melki, V., & Zinman, B. (2004). Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections. Diabetes Care. https://doi.org/10.2337/diacare.27.11.2590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.